156 related articles for article (PubMed ID: 7754801)
1. The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site.
Boyce RW; Paddock CL; Gleason JR; Sletsema WK; Eriksen EF
J Bone Miner Res; 1995 Feb; 10(2):211-21. PubMed ID: 7754801
[TBL] [Abstract][Full Text] [Related]
2. Effects of intermittent hPTH(1-34) alone and in combination with 1,25(OH)(2)D(3) or risedronate on endosteal bone remodeling in canine cancellous and cortical bone.
Boyce RW; Paddock CL; Franks AF; Jankowsky ML; Eriksen EF
J Bone Miner Res; 1996 May; 11(5):600-13. PubMed ID: 9157775
[TBL] [Abstract][Full Text] [Related]
3. Partial maintenance of extra cancellous bone mass by antiresorptive agents after discontinuation of human parathyroid hormone (1-38) in right hindlimb immobilized rats.
Ma Y; Jee WS; Chen Y; Gasser J; Ke HZ; Li XJ; Kimmel DB
J Bone Miner Res; 1995 Nov; 10(11):1726-34. PubMed ID: 8592950
[TBL] [Abstract][Full Text] [Related]
4. Extra cancellous bone induced by combined prostaglandin E2 and risedronate administration is maintained after their withdrawal in older female rats.
Jee WS; Lin BY; Ma YF; Ke HZ
J Bone Miner Res; 1995 Jun; 10(6):963-70. PubMed ID: 7572321
[TBL] [Abstract][Full Text] [Related]
5. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis.
Storm T; Steiniche T; Thamsborg G; Melsen F
J Bone Miner Res; 1993 Feb; 8(2):199-208. PubMed ID: 8442438
[TBL] [Abstract][Full Text] [Related]
6. Bone remodeling at the iliac crest can predict the changes in remodeling dynamics, microdamage accumulation, and mechanical properties in the lumbar vertebrae of dogs.
Mashiba T; Hui S; Turner CH; Mori S; Johnston CC; Burr DB
Calcif Tissue Int; 2005 Sep; 77(3):180-5. PubMed ID: 16265598
[TBL] [Abstract][Full Text] [Related]
7. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
[TBL] [Abstract][Full Text] [Related]
8. The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover.
Borah B; Ritman EL; Dufresne TE; Jorgensen SM; Liu S; Sacha J; Phipps RJ; Turner RT
Bone; 2005 Jul; 37(1):1-9. PubMed ID: 15894527
[TBL] [Abstract][Full Text] [Related]
9. Effect of risedronate on osteocyte viability and bone turnover in paired iliac bone biopsies from early postmenopausal women.
Qiu S; Phipps RJ; Ebetino FH; Palnitkar S; Sudhaker Rao D
Calcif Tissue Int; 2010 Nov; 87(5):392-7. PubMed ID: 20809096
[TBL] [Abstract][Full Text] [Related]
10. Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis.
Ste-Marie LG; Sod E; Johnson T; Chines A
Calcif Tissue Int; 2004 Dec; 75(6):469-76. PubMed ID: 15478000
[TBL] [Abstract][Full Text] [Related]
11. Effects of the bisphosphonate YM175 on bone mineral density, strength, structure, and turnover in ovariectomized beagles on concomitant dietary calcium restriction.
Motoie H; Nakamura T; O'uchi N; Nishikawa H; Kanoh H; Abe T; Kawashima H
J Bone Miner Res; 1995 Jun; 10(6):910-20. PubMed ID: 7572315
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.
Brown JP; Kendler DL; McClung MR; Emkey RD; Adachi JD; Bolognese MA; Li Z; Balske A; Lindsay R
Calcif Tissue Int; 2002 Aug; 71(2):103-11. PubMed ID: 12085156
[TBL] [Abstract][Full Text] [Related]
13. Risedronate: clinical usage.
Chapurlat RD; Delmas PD
Int J Clin Pract; 2001 May; 55(4):275-8. PubMed ID: 11406915
[TBL] [Abstract][Full Text] [Related]
14. Short-term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: a dose response study.
Brixen K; Kassem M; Nielsen HK; Loft AG; Flyvbjerg A; Mosekilde L
J Bone Miner Res; 1995 Dec; 10(12):1865-74. PubMed ID: 8619366
[TBL] [Abstract][Full Text] [Related]
15. Skeletal effects of constant and terminated use of sodium risedronate in ovariectomized rats.
Li QN; Liang NC; Huang LF; Wu T; Hu B; Mo LE
Zhongguo Yao Li Xue Bao; 1998 Mar; 19(2):160-3. PubMed ID: 10374643
[TBL] [Abstract][Full Text] [Related]
16. Calcitonin prevents bone loss but decreases osteoblastic activity in ovariohysterectomized beagle dogs.
Monier-Faugere MC; Geng Z; Qi Q; Arnala I; Malluche HH
J Bone Miner Res; 1996 Apr; 11(4):446-55. PubMed ID: 8992875
[TBL] [Abstract][Full Text] [Related]
17. Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia.
Dane C; Dane B; Cetin A; Erginbas M
Gynecol Endocrinol; 2008 Apr; 24(4):207-13. PubMed ID: 18382907
[TBL] [Abstract][Full Text] [Related]
18. Alendronate (Fosamax) and risedronate (Actonel) revisited.
Med Lett Drugs Ther; 2005 Apr; 47(1207):33-5. PubMed ID: 15843782
[TBL] [Abstract][Full Text] [Related]
19. The mineralization of bone tissue: a forgotten dimension in osteoporosis research.
Boivin G; Meunier PJ
Osteoporos Int; 2003; 14 Suppl 3():S19-24. PubMed ID: 12730799
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
